Formosa Pharmaceuticals, Inc.’s Post

Exciting News: 🚀 The Next Generation Ophthalmic Steroid Is Now Available in the US! 🚀 Thrilled to announce the commercial U.S. launch of clobetasol propionate ophthalmic suspension 0.05% (APP13007) developed by Formosa Pharmaceuticals, Inc. This highly anticipated development brings a formidable therapy to ocular surgery patients in the U.S. in partnership with Eyenovia, Inc. #ClobetasolBID #APP13007 #USLaunch

  • graphical user interface, text
Clinton Sheets

President and Ophthalmologist at Advanced Cataract & Glaucoma Care, PLLC

2mo

Where does this fit in compared to other available topical steroids? Stronger, weaker, less glaucoma, etc?

Like
Reply

To view or add a comment, sign in

Explore topics